Loading
Metastasis and Carcinoma Case Studies / Cancer and Skin Lesions / Breast Lesions and Carcinomas · Journal article
Frontiers in Oncology · September 9, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a single case report of a 66-year-old woman with Stage I invasive lobular carcinoma with signet-ring-cell differentiation treated with neoadjuvant chemotherapy, breast-conserving surgery, radiotherapy, and capecitabine. The case documents clinical presentation, pathological findings, and treatment response but does not provide evidence to guide clinical practice for this rare subtype.
Case report. Single 66-year-old woman presenting for routine breast cancer screening with no subjective symptoms; diagnosed with invasive lobular carcinoma with signet-ring-cell differentiation in the upper-outer region of the right breast. Intervention: Neoadjuvant chemotherapy (4 cycles of epirubicin and cyclophosphamide followed by 4 cycles of docetaxel), breast-conserving surgery with sentinel lymph node biopsy, postoperative radiotherapy, and 8 cycles of capecitabine.
Core needle biopsy diagnosed ILC with signet-ring-cell differentiation; cT1cN0M0, Stage I at presentation Immunohistochemistry showed ER-positive (10%, weak), PgR-negative (0%), HER2 score 0, Ki-67 index 9.8% Patient received 4 cycles of epirubicin and cyclophosphamide followed by 4 cycles of docetaxel as neoadjuvant chemotherapy with 80% relative dose intensity
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This case demonstrates one instance of treatment with multidisciplinary therapy for a rare breast cancer subtype but does not provide evidence sufficient to guide management decisions. Clinicians should recognize that ILC with signet-ring-cell differentiation can present as early-stage disease and may respond to neoadjuvant chemotherapy, but generalizable outcomes data are lacking.
Single case report of rare breast cancer histology treated with multidisciplinary therapy; describes clinical course and treatment response but provides no comparative data, control arm, or generalizable evidence.
As stated by the source record.
Quoted from the source exactly as published.
This case demonstrates one instance of treatment with multidisciplinary therapy for a rare breast cancer subtype but does not provide evidence sufficient to guide management decisions. Clinicians should recognize that ILC with signet-ring-cell differentiation can present as early-stage disease and may respond to neoadjuvant chemotherapy, but generalizable outcomes data are lacking.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Background Invasive lobular carcinoma (ILC) with signet-ring-cell (SRC) differentiation of the breast is a relatively rare disease and is reported to frequently metastasize to the gastrointestinal and urinary systems. Case presentation A 66-year-old woman presented for routine breast cancer screening without any subjective symptoms. A mass detected in the upper-outer region of her right breast. Core needle biopsy led to the diagnosis of ILC with SRC of the breast. Positron emission tomography-computed tomography, urine cytology, and upper and lower gastrointestinal endoscopy revealed no abnormal findings, and the disease was diagnosed as cT1cN0M0, Stage I. Immunohistochemical examination showed estrogen receptor (ER)-positive (10%, weak), progesterone receptor (PgR)-negative (0%), human-epidermal growth factor receptor 2 (HER2) score 0, and Ki-67 index of 9.8%, suggesting a luminal B-like subtype. The patient received 4 cycles of epirubicine and cyclophosphamide followed by 4 cycles of docetaxel (DTX) as neoadjuvant chemotherapy (NAC). Because prolonged neutropenia occurred during DTX treatment, temporary treatment interruptions were required; however, all cycles were completed with a relative dose intensity of 80%. As stable disease after completion of NAC, right breast-conserving surgery with sentinel lymph node biopsy was performed. Pathological assessment after neoadjuvant chemotherapy revealed ypT1c (1.8 cm) sN0 (0/1), therapeuthic effect Grade 2b, ER- (0%), PgR- (0%), HER2 0, Ki-67 20% of residual tumor remaining in the breast. Therefore, BRACAnalysis ® testing was performed as a companion diagnostic test and was negative. The patient subsequently have received postoperative radiotherapy, and 8 cycles of capecitabine therapy. Conclusions In our cohort of ILC patients treated at our institution, we also observed cases with gastrointestinal metastases; therefore, attention should be paid to symptoms and findings suggestive of metastasis to these sites as well.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.